Appendix Table C29. Study withdrawals and adverse events (outcomes part D), ACEI plus ARB versus ACEI plus aldosterone antagonist trial

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Study Withdrawals, Any, n/N (%)** | | **Serious Adverse Events, Any, n/N (%)** | | **Withdrawals Due to Adverse Events, Any, n/N (%)** | | **Adverse Events, Any, n/N (%)** | | **Adverse Events, Specific, n/N (%)** | | **Renal Adverse Events, Any, n/N (%)** | |
| **ACEI+**  **ARB** | **ACEI+**  **AA** | **ACEI+**  **ARB** | **ACEI+**  **AA** | **ACEI+**  **ARB** | **ACEI+**  **AA** | **ACEI+**  **ARB** | **ACEI+**  **AA** | **ACEI+**  **ARB** | **ACEI+**  **AA** | **ACEI+**  **ARB** | **ACEI+**  **AA** |
| Mehdi, 200945 | 9/27 (33.3) | 10/27 (37.0) |  |  | 2/26 (7.7) | 7/27 (25.9) |  |  | 0/26 (0.0) | 1/27 (3.7) | Recurrent hyperkalemia: 0/26; Withdrawn due to increased SCr: 0/27 | Recurrent hyperkalemia: 2/27 (7.4); Withdrawn due to increased SCr: 1/27 |

ACEI = angiotensin converting enzyme inhibitor; ARB = antiogensin receptor blocker; AA = aldosterone antagonist ; SCr = serum creatinine